Literature DB >> 1657029

Kaposi's sarcoma: its 'oncogenes' and growth factors.

J G Sinkovics1.   

Abstract

Viral genes capable of inducing vascular tumors in the skin of transgenic mice are the tat gene of HIV-1 and polyoma virus' middle T antigen gene. Instead of vascular tumors, the tat gene of HTLV-I causes thymic atrophy and mesenchymal tumors in transgenic mice. No proof exists that any of these genes contribute to the induction of KS but HIV-1 tat is a strong suspect. The gene product K-FGF of the oncogene K-fgf/hst (int) uses bFGF receptors, is homologous with bFGF and acts as a mitogen for fibroblasts, endothelial cells and melanocytes. The overexpression of the K-fgf gene in KS is not proven unequivocally; some doubts exist suggesting the activation of this gene during the laboratory procedure of transfection with KS cell heavy DNA. Growth factor(s) not well identified (IL-6?) are released from HTLV-I- or II, or HIV-1- or 2-infected T4 lymphocytes and in particular from HIV-1-infected macrophages. This growth factor(s) promote(s) the continuous proliferation of endothelial cells and KS cells. AIDS-KS cells release other growth factors identical with or closely related to basic FGF, a major inducer of angioneogenesis. In addition, acidic FGF, IL-1 alpha and -beta, GM-CSF, PDGF-B and TGF-beta are released from AIDS-KS cells. The release of GM-CSF is induced by IL-1. GM-CSF promotes granulocytic, monocytic and endothelial cell proliferation. TGF-beta is known to suppress lymphocyte-mediated cytotoxicity and may act as a local immunosuppressive factor together with interferon inactivators. We theorize that when TGF-beta production ceases, TNF-beta (lymphotoxin) production switches on leading to programmed cell death (apoptosis) of KS cells resulting in regression of these lesions. The newly discovered angiogenesis factors VEGF/VPF may emerge as protooncogene-oncogene products analogous to PDGF and c-sis activation. AIDS-KS heavy DNA transfects NIH3T3 cells. NIH3T3 cells carrying this gene induced angiosarcomas when implanted in mice. An as yet unidentified large virus (mycoplasma?) was derived from these cells during passages in culture. No causative relationship between this agent and Kaposi sarcoma has as yet been established. Even though IFN-alpha exerts antiretroviral effects in AIDS, we propose that the therapeutic effect of IFN-alpha in AIDS-KS is based on antiangiogenesis activity by suppressing protooncogenes-oncogenes of the FGF family.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657029     DOI: 10.1016/1040-8428(91)90001-s

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  6 in total

1.  Contradictory Concepts in the Etiology and Regression of Kaposi's Sarcoma. The Ferenc Györkey Memorial Lecture.

Authors:  Joseph G Sinkovics
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 2.  Interferons as antiangiogenic agents.

Authors:  Daniel J Lindner
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

3.  Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression.

Authors:  Zaklyah Kadry; Oscar Bronsther; David H Van Thiel; Parmjeet Randhawa; John J Fung; Thomas E Starzl
Journal:  Clin Transplant       Date:  1993-01-01       Impact factor: 2.863

4.  Detection of Kaposi's sarcoma-associated herpesvirus-like DNA sequence in angiosarcoma.

Authors:  D P McDonagh; J Liu; M J Gaffey; L J Layfield; N Azumi; S T Traweek
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

5.  Endothelial cell proliferation associated with lesions of murine systemic candidiasis.

Authors:  R B Ashman; J M Papadimitriou
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

6.  P311 Facilitates the Angiogenesis and Wound Healing Function of MSCs by Increasing VEGF Production.

Authors:  Zhihui Liu; Jiacai Yang; Yunxia Chen; Cheng Chen; Jue Wang; Yew Mun Lee; Wenxia Zheng; Ruoyu Shang; Yuanyang Tang; Xiaorong Zhang; Xiaohong Hu; Yong Huang; Shiya Peng; Yih-Cherng Liou; Weifeng He; Gaoxing Luo
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.